Unlock superior protein expression with 2G UNic®

A premium vector and transposon platform delivering higher yields and faster cell line development in CHO and HEK systems.

Trusted by leading biotech and CDMO partners

2G UNic is trusted by leading biotechnology companies and CDMOs worldwide to deliver higher-yield production and improved manufacturing performance across biologics, biosimilars and advanced therapies.

Why leading biopharma teams adopt 2G UNic

Proven across monoclonal antibodies, biosimilars, and complex or difficult-to-express biologics

  • Increase titers without re-engineering your process
  • Shorten cell line development timelines
  • Improve success rates for complex molecules
  • Reduce cost of goods and manufacturing risk

What 2G UNic delivers

2G UNic enables higher, more stable protein expression across CHO and HEK systems, supporting monoclonal antibodies, biosimilars, and complex biologics, without requiring changes to existing workflows.

By improving both transcription and translation efficiency, the platform delivers stronger expression, more reliable cell lines, and faster progression from transfection to production.

Representative data showing up to 10 g/L  titers achieved with 2G UNic in CHO and HEK expression systems.

Consistently higher titers across programs

Across multiple studies and protein formats, 2G UNic consistently delivers 2–5× higher titers in CHO and HEK expression systems compared to standard vectors. These gains are observed across:
  • Monoclonal antibodies, Fc-fusions, and bispecific formats
  • Multiple CHO host systems (CHO-K1, CHO-S, DG-44, and GS-based platforms)
  • Standard selection and development workflows
The impact is:
  • Faster identification of high-producing clones
  • More reliable scale-up and process performance
  • Reduced development timelines and improved manufacturing economics

Higher productivity by design

Vector architecture engineered to maximise transcription and translation efficiency

More reliable integration

Semi-targeted transposon integration improves consistency compared to random methods

Fits your existing workflow

No changes required to host systems, selection strategies, or development processes

Clinically validated

Used in molecules progressing to late-stage development and trusted by leading CDMOs

  • A unique dual-promoter structure ensures balanced transcriptional output, while epigenetically optimized control elements prevent silencing and maintain long-term stability.
  • Translation enhancers further increase protein synthesis efficiency, enabling high productivity without compromising product quality.

@Jonathan, can you make a title here?

  • A unique dual-promoter structure ensures balanced transcriptional output, while epigenetically optimized control elements prevent silencing and maintain long-term stability.
  • Translation enhancers further increase protein synthesis efficiency, enabling high productivity without compromising product quality.

How it delivers more protein per gene copy?

  • Each 2G UNic expression cassette is engineered to maximize both transcription and translation efficiency.
  • More mRNA per integrated DNA copy
  • The dual-promoter design keeps every integrated gene copy transcriptionally active.
  • Epigenetically optimized regulatory elements prevent silencing and sustain long-term expression, resulting in higher mRNA levels across cell populations.
  • More protein per mRNA molecule
  • An optimized 5′ UTR improves ribosome binding while enhancing mRNA stability and intracellular transport. As a result, each mRNA molecule produces more protein before degradation, increasing productivity without affecting product quality.

Together, these mechanisms amplify protein synthesis at every stage, producing more mRNA, more protein, and ultimately higher titers per integrated gene copy in both CHO and HEK systems.

2G UNic vector technology integrates seamlessly with leading transposon systems, including 2G UNic Transposon, PiggyBac, Sleeping Beauty, and others, enabling flexible, high-yield cell-line development and manufacturing workflows.

When paired with major transposon platforms, 2G UNic vector technology consistently increases expression levels and accelerates cell-line development in both CHO and HEK systems.

Combining optimized expression with efficient integration

2G UNic improves transcription and translation at the vector level.

When combined with transposon-based integration, this translates directly into:

  • Higher titers from stable pools and clones
  • More consistent expression across cell populations
  • Less time spent screening and selecting high producers

The platform can be used with existing transposon systems or as part of the full 2G UNic Transposon solution, depending on your development strategy.

2G UNic vector technology is adaptable across multiple expression systems.

Beyond its proven performance in mammalian hosts such as CHO and HEK, the platform has also been successfully implemented in yeast (Pichia pastoris / Komagataella phaffii) for efficient production of recombinant proteins, enzymes, and vaccine antigens.

The same principles of transcriptional control and translational enhancement that drive mammalian performance can also support productivity in microbial systems.

Mammalian Expression (CHO / HEK)

High-yield transient and stable expression of antibodies, Fc-fusions, and other recombinant proteins using 2G UNic Vector Technology.

Producer & Packaging Cell Lines

Rapid, stable generation of high-yield producer and packaging lines for viral-vector manufacturing.

Microbial Expression (Yeast)

Efficient secretion of enzymes and vaccine antigens in Pichia pastoris / Komagataella phaffii using 2G UNic Vector Technology.

2G UNic integrates directly into standard CHO and HEK cell-line development workflows without requiring proprietary host systems or extensive revalidation.

It is compatible with common selection markers, vector backbones, and transposon systems, enabling rapid evaluation and scale-up within existing platforms. Applicable across monoclonal antibodies, biosimilars, and complex biologics.

CDMOs and biopharma developers can adopt 2G UNic as:

  • A plug-in vector solution to enhance existing expression workflows
  • A complete transposon-based platform for maximum productivity gains

Flexible adoption pathway

  • Direct implementation – integrate 2G UNic into your current workflow to immediately improve expression and productivity
  • Optional evaluation – generate internal data where additional validation is required
  • Scale-up – move seamlessly into manufacturing with consistent performance and full support

Higher Titers

3–10× titer boost

Faster CLD

30 – 50% shorter CLD timelines

Stable

Expression maintained